Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joel Pickett

Neurological Surgery Huntsville, AL Medical Doctor

NPI 1023019445 CMS profile 182664

201 Governors Drive 1St Floor, Huntsville, AL 35801

Open in the dashboard

General payments

$71,521

43 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joel Pickett of Huntsville, AL is reported in the CMS Open Payments database as having received $71,521 across 43 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,117 9
2024 General $1,859 7
2023 General $1,195 13
2022 General $124 4
2021 General $15 1
2020 General $48 2
2019 General $58,163 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joel Pickett
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Joel Pickett were reported at $10,117. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Joel Pickett Neurological Surgery median Middle half National median
2019 $58,163 $582 $138–$3,006 $163
2020 $48 $294 $76–$2,174 $114
2021 $15 $387 $105–$2,432 $132
2022 $124 $542 $139–$2,989 $149
2023 $1,195 $534 $145–$2,697 $160
2024 $1,859 $574 $155–$3,046 $164
2025 $10,117 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. North Alabama Surgical Services, LLC $57,408 1 payment
  2. Curiteva, Inc. $12,276 5 payments
  3. Globus Medical, Inc. $992 8 payments
  4. Providence Medical Technology, Inc. $225 6 payments
  5. Arteriocyte Medical Systems, Inc. $92 2 payments
  6. NuVasive, Inc. $84 2 payments
  7. Prime Surgical, LLC $64 2 payments
  8. Orthofix Medical, Inc. $63 3 payments
  9. Stryker Corporation $55 2 payments
  10. DePuy Synthes Sales Inc. $43 2 payments
  11. Other $219 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Current or prospective ownership or investment interest $57,408 1 payment
  2. Royalty or License $11,557 2 payments
  3. Food and Beverage $1,649 34 payments
  4. Travel and Lodging $907 6 payments
Products named General payments · program years 2019–2025
  1. ExcelsiusGPS Robotic Navigation System $964 7 payments
  2. Magellan $92 2 payments
  3. Modulus $84 2 payments
  4. Medical Devices $76 2 payments
  5. TLIF $48 1 payment
  6. Spinal-Stim $37 2 payments
  7. NICO BRAINPATH $35 1 payment
  8. FLOSEAL $28 1 payment
  9. EXCELSIUS GPS $28 1 payment
  10. Cervical-Stim Osteogenesis Stimulator $26 1 payment
  11. Other $349 17 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

482

Median for Neurosurgery: 83

Drug cost

$3,608

Median for Neurosurgery: $872

Branded share of claims

30.3%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methocarbamol Generic 174 $1,339
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 67 $759
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 79 $732
Methylprednisolone Generic 54 $364
Meloxicam Generic 69 $210
Levetiracetam Generic 16 $190
Diazepam Generic 23 $12

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 80 billing codes

Paid by Medicare

$178,357

Of which drugs: $48

Medicare patients

506

Average age 74

Services billed

1,655

292 women, 214 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 39%
Diabetes 35%
Depression 33%
Chronic kidney disease 25%
Atrial fibrillation 19%
COPD 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

43 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record